Navigation Links
multiforme in Medical News

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

Small molecule drug inhibits key DNA repair mechanism involved in resistance DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therap...

National Cancer Coalition Announces Angel Grant Recipients

...ersity of Chicago's Comer Children's Hospital. His Angel Grant will be used to further his investigations of the biology of pediatric Glioblastoma multiforme (GBM) brain tumors and their treatment. The National Cancer Coalition implemented its Angel Grant program to provide seed funding to innovati...

Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved

...ines in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an impr...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

... The Company provided an update on several of its clinical programs: AMG 102: In Phase 2 studies, limited efficacy was seen in glioblastoma multiforme and renal cell carcinoma when AMG 102 was administered in monotherapy, but the effect size was not large enough to warrant moving forward with late-st...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

...nts in the initial two cohorts of the study have all either met or exceeded the expected median survival time of six months for recurrent glioblastoma multiforme (GBM) patients. Presented data at the Society of Nuclear Medicine 2009 Annual Meeting showing that Cotara specifically localizes to brain tumors...

Most common brain cancer may start in neural stem cells

...ations are highly plastic. If a treatment blocks one path of action, they may learn other ways to grow," Zhu says. That helps explain why glioblastoma multiforme returns in drug-resistant forms. Research details: Zhu's team conducted a series of experiments using mice engineered to have a p53 mutation i...

Most common brain cancer may originate in neural stem cells

...ations are highly plastic. If a treatment blocks one path of action, they may learn other ways to grow," Zhu says. That helps explain why glioblastoma multiforme returns in drug-resistant forms. Research details: Zhu's team conducted a series of experiments using mice engineered to have a p53 mutation i...

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

...in a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that patie...an drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A Pha...

NCCN Updates Guidelines for Central Nervous System (CNS) Cancers

...ommendation to use bevacizumab as a single agent for recurrent glioblastoma multiforme in CNS cancers, the integration of a patient's Karnofsky Performance Status...worthy change in the updated NCCN Guidelines for patients with glioblastoma multiforme is the integration of a patient's Karnofsky Performance Status (KPS) score ...

Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer

...tocellular Carcinoma (Abstract #e15684)" and "A Phase 2a Study of Light-Activated Talaporfin Sodium in Patients with Primary or Recurrent Glioblastoma multiforme (Abstract #e13026)." About Aptocine Aptocine (talaporfin sodium) is a water-soluble drug activated by an included small, single-use, disposable...
multiforme in Medical Technology

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

- PFS data from Neuradiab(TM) compares favorably to data from other technologies - TSX: BMR TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today release...

Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme

Celldex also receives approval from Health Canada to open clinical sites and establishes a collaboration with the National Cancer Institute PHILLIPSBURG, N.J., Dec. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug...

Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme

LOS ANGELES, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. and the European Organisation for the Research and Treatment of Cancer (EORTC) announced long-term follow-up results from the landmark Phase III trial conducted by the EORTC and the National Cancer Institute of Canada (NCIC) ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... mg/kg) for 1-2 weeks concomitantly with imatinib should be considered at the initiation of therapy. Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe p...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

... General Poster Session, May 31, 2:00 p.m.-6:00 p.m. Glioma Fiveash J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 8:00 a.m.-12:00 p.m. Lung Cancer Heist R, et al. A phase I/II study of A...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...post-approval use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal). About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmac...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

...post-approval use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal). About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceu...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

...talities, of cardiac tamponade, cerebral edema, acute respiratory failure, and GI perforation. Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several post marketing reports describe...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

...nce and flexibility. TEMODAL Capsules are a chemotherapy agent approved in the EU for treatment of patients with newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and subsequently as monotherapy, and for patients with malignant gliomas, such as GBM or anaplastic astrocytoma ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...atalities, of cardiac tamponade, cerebral edema, acute respiratory failure and GI perforation. Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several post-marketing reports describe...
multiforme in Medical Dictionary

Erythema multiforme

Erythema multiforme is a skin condition of unknown etiology, possibly mediated by deposition of immune complex ( mostly IgM ) in the superficial microvasculature of the skin and oral mucous membrane that usually follows an antecedent infection or drug exposure. It is a... Erythem...

Erythema

..., guttate on the arms and chest ... Erythema multiforme on the hand. Exfoliation following erythroderma ... Erythema multiforme is a skin disorder due to an allergic reaction o...atous, subcutaneous nodules ... Erythema multiforme is a skin condition considered to be a hypersens...
multiforme in Biological News

UNC study: Scientists identify chemical compound that may stop deadly brain tumors

...icular gene mutation contributes to tumor growth. The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers from. A...

Salk researchers develop novel glioblastoma mouse model

...re suspected to be the origin of glioblastoma. Within a few months, massive tumors that displayed all the histological characteristics of glioblastoma multiforme preferentially developed in the hippocampus and the subventricular zone. The ability of adult stem cells to divide and generate both new stem cell...

Investigating the measles virus as a tool to kill multiple myeloma

...therapies being tested today in several tumor types, including glioblastoma multiforme (a brain tumor), recurrent ovarian cancer and now multiple myeloma. T...on of higher and potentially even more potent viral doses. The glioblastoma multiforme trial, which opened in the fall, is testing the safety of another strain of...

Killing brain tumors from within: A 'Trojan horse' approach

...mber of epidermal growth factor receptors (EGFR). This proliferation of EGFR is typical of certain types of cancer cells, including glioblastoma multiforme (GBM), the most lethal form of brain cancer. The nucleic acid-EFG molecule acts as a "guided missile," explained Prof. Levitzki, which, when inj...

Scientist works to improve treatment for brain tumors

...drug that he developed for the most deadly type of brain tumor. Waldemar Debinski, M.D., Ph.D., pioneered a method to destroy cells of glioblastoma multiforme (GBM) with less damage to healthy cells. The drug is currently being tested in clinical trials and Debinski is working on its fourth generation in the...

Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer

...oncologist and lead researcher on the glioblastoma multiforme project in the measles virus investigation. "We h..., seek out this protein, entering the glioblastoma multiforme tumor. Upon entry, the virus begins to spread, in...ven more potent viral doses." The glioblastoma multiforme study, which opened today, is designed to test the...

Radiotherapy advance points way to noninvasive brain cancer treatment

... With an equal rate of incidence and mortality-the number of those who get it, and the number of those who die from it-Glioblastoma multiforme (GBM) is a brain cancer death sentence. Of the approximately 12,000 people who are diagnosed with GBM annually in the U.S., half will die within a y...

Preclinical study of a new brain tumor therapy

...ling the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM). This is the most aggressive form of brain tumour, growing very quickly before symptoms are experienced and killing most patients within a year ...

'Smart drug' targets deadly brain cancer

...Organization categorizes fast-growing glioblastoma multiforme as a grade IV cancer. Significance of the Mayo ...6 percent) of patients with recurrent glioblastoma multiforme participating in this study -- which is a high res...ned to target specific changes in the glioblastoma multiforme tumor cells that previous studies have identified ...
multiforme in Biological Technology

Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models

...drugs. In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma multiforme (GBM), the most common and aggressive brain tumor of adults, and also, marked regression of neuroblastoma, the most common cancer of children. Temozol...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... radioisotope being developed as a potential new treatment for glioblastoma multiforme (GBM), a deadly form of brain cancer. The results reported today from an o...an drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A Pha...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

...ponsored Phase II study of AT-101 as monotherapy for recurrent glioblastoma multiforme (GBM), the most aggressive form of brain cancer, were also presented(3) . F...h J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 8:00 a....

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

...s study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma. Enquiries Dr. Gregg Smith Mr. Andrew Macdonald Director, Drug Development and Oper...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

...0, 2009, 1:00 pm - 5:00 pm) -- Dual targeting of the receptor tyrosine kinase EGFRvIII and HGF:c-Met signaling in models of glioblastoma multiforme (GBM) Overview: Examined the effect of combining a fully human neutralizing antibody targeting the HGF:c-Met axis (AMG 102), with a fu...

Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results

...elopment when we receive the results of an ongoing 113 patient Phase 2 clinical trial of MGd combined with radiation plus temozolomide in glioblastoma multiforme (GBM). This trial is being conducted by the Radiation Therapy Oncology Group (RTOG) with results expected in late 2010." "Our management team h...

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

...0 days on Bradmer's website. About Glioblastoma Multiforme Glioblastoma multiforme (GBM) is the most common and most advanced form of brain cancer with approx...onal antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab de...

SuperGen Reports 2008 Third Quarter Financial Results

...August 2008: The Company announced that the FDA granted orphan drug designation for our lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. The FDA accepted the Company's application upon review of data from in vitro studies in glioblastoma cell ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

...1-2 mg/kg) for 1-2 weeks concomitantly with imatinib should be considered at the initiation of therapy. Bullous dermatologic reactions (eg, erythema multiforme and Stevens- Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several postmarketing reports describe...

Northwest Biotherapeutics to Present at Next Generation Vaccine Conference

...r. Boynton will provide an update on NWBT's product candidates, including therapeutic cancer vaccines DCVax(R)-Brain for the treatment of Glioblastoma multiforme and DCVax(R)-Prostate for hormone-independent prostate cancer. About Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology compan...
Other Tags
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... 2014 Each year trauma accounts for ... hospital admissions across the nation (according to the ... CDC’s National Hospital Ambulatory Medical Care Survey collected ... in 2010. They estimated that there were between 3.5 ... a primary diagnosis of broken bone or fracture. ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
Other Contents